Abstract | OBJECTIVE: Fetal safety has never been studied for any drug used in the treatment of hemorrhoids. Proctofoam-HC is a combination of a corticosteroid and a local anaesthetic that is proven effective for the treatment of hemorrhoids. The objective of this study was to assess prospectively the fetal safety of third trimester exposure to Proctofoam-HC. METHODS: In a multicentre study, 204 [corrected] women exposed to Proctofoam-HC in the third trimester and a similar number of control pregnant women were followed up postnatally. RESULTS: When compared to controls exposure to Proctofoam-HC was not associated with any adverse fetal effects on birth weight, gestational age, rates of prematurity, or pre- or postnatal complications. CONCLUSION:
|
Authors | Neda Ebrahimi, Sabina Vohra, Christelle Gedeon, Hani Akoury, Paul Bernstein, Nicholas Pairaudeau, Johanne Cormier, Lorraine Dontigny, Marc-Yvon Arsenault, Claude Fortin, Martine Goyet, Chantal Lafortune, Johanne Lalande, Coralie Beauchamp, Francis Engel, Anne Fortin, Anna Taddio, Tom Einarson, Gideon Koren |
Journal | Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC
(J Obstet Gynaecol Can)
Vol. 33
Issue 2
Pg. 153-158
(Feb 2011)
ISSN: 1701-2163 [Print] Netherlands |
PMID | 21352635
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anesthetics, Local
- Anti-Inflammatory Agents
- Drug Combinations
- Morpholines
- proctofoam-HC
- Hydrocortisone
|
Topics |
- Adult
- Anesthetics, Local
(adverse effects)
- Anti-Inflammatory Agents
(adverse effects)
- Birth Weight
- Drug Combinations
- Female
- Fetal Development
(drug effects)
- Hemorrhoids
(drug therapy)
- Humans
- Hydrocortisone
(adverse effects)
- Morpholines
(adverse effects)
- Pregnancy
- Pregnancy Complications
(drug therapy)
- Pregnancy Trimester, Third
|